GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a strategic business agreement to develop the first circular RNA-based anticancer drug in South Korea.
With this strategic partnership, both companies will establish the first large-scale production process for circular RNA therapeutics in South Korea from preclinical to clinical stages (with GMP production). This also serves as a…